Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ÁÂ¾à Æ÷Àå ½ÃÀåÀº 2024³â¿¡ 4¾ï 2,304¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ Áß CAGR 7.7%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 6¾ï 6,020¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Á¾àÀÇ º¸È£, º¸°ü ¹× Åõ¿©¸¦ À§ÇØ ¸¸µé¾îÁø Ư¼ö Æ÷Àå ¿É¼ÇÀ» ÁÂ¾à Æ÷ÀåÀ̶ó°í ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Æ÷ÀåÀº Á¦Ç°ÀÇ ¹«°á¼º, À§»ý ½À°ü, º¹¿ëÀÇ Æí¸®ÇÔÀ» º¸ÀåÇÏ¸é¼ ¿À¿°À¸·ÎºÎÅÍ º¸È£ÇÕ´Ï´Ù. Á¦Ç°ÀÇ È¿´ÉÀ» À¯ÁöÇϱâ À§ÇØ ÁÂ¾à Æ÷ÀåÀº ½À±â, ºû, ¿Âµµ º¯È¿¡ ´ëÇÑ À庮 º¸È£ ±â´ÉÀ» Á¦°øÇØ¾ß ÇÕ´Ï´Ù. Áú ¹× Á÷Àå Á¾àÀ¸·Î Á¦¾à ¹× ÀÇ·á ºÐ¾ß¿¡¼ ³Î¸® »ç¿ëµË´Ï´Ù.
ÀÇ·áºñ ÁöÃâ Áõ°¡
¼¼°è ÇコÄɾî ÁöÃâ Áõ°¡´Â ÁÂ¾à Æ÷Àå ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁøÁ¦ÀÔ´Ï´Ù. Á¤ºÎ¿Í °³ÀÎÀÌ ÀÇ·á¿¡ ´õ ¸¹Àº ÀÚ¿øÀ» ÇÒ´çÇÔ¿¡ µû¶ó Á¾àÀ» Æ÷ÇÔÇÑ ÀǾàǰ¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀçÁ¤Àû Çå½ÅÀº ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³¹ß ¹× äÅÃÀ» °¡´ÉÇÏ°Ô ÇÏ°í °íǰÁú Æ÷Àå ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¼±Áø±¹ÀÇ °í·ÉÈ´Â °í·ÉÃþÀÌ ´õ ¸¹Àº ÀǾàǰÀ» ÇÊ¿ä·Î ÇϹǷΠÀÌ·¯ÇÑ Ãß¼¼¸¦ ´õ¿í °¡¼ÓȽÃ۰í ÀÖ½À´Ï´Ù.
¾ö°ÝÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ
FDA¿Í °°Àº ±ÔÁ¦±â°üÀº Á¦Ç°ÀÇ ¾ÈÀü¼º, ¾ÈÁ¤¼º, À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ ÀǾàǰ Æ÷Àå¿¡ ¾ö°ÝÇÑ ±âÁØÀ» Àû¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦·Î ÀÎÇØ ´ë±Ô¸ð Å×½ºÆ®, ¹®¼È ¹× ±ÔÁ¤ Áؼö ÀýÂ÷°¡ ÇÊ¿äÇϸç, Á¦Ç° °³¹ß ±â°£ÀÌ ±æ¾îÁö°í Á¦Á¶¾÷üÀÇ ºñ¿ëÀÌ Áõ°¡ÇÕ´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦´Â Áö¿ª¸¶´Ù ´Ù¸£±â ¶§¹®¿¡ ±â¾÷Àº °¢±â ´Ù¸¥ ½ÃÀå¿¡¼ ¼·Î ´Ù¸¥ ±âÁØÀ» ÃæÁ·½Ã۱â À§ÇØ Æ÷Àå ¼Ö·ç¼ÇÀ» Á¶Á¤ÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦´Â ƯÈ÷ º¹ÀâÇÑ ±ÔÁ¦ ȯ°æÀ» ±Øº¹ÇÏ´Â µ¥ ÇÊ¿äÇÑ Àڱݰú ±â¼ú ¸®¼Ò½º¸¦ È®º¸ÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖ´Â Áß¼Ò Á¦Á¶¾÷ü¿¡ ƯÈ÷ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù.
Æ÷ÀåÀç Çõ½Å
»ýºÐÇØ¼º ¹× ģȯ°æ ¼ÒÀçÀÇ °³¹ßÀº ȯ°æ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¦¾à¾÷°èÀÇ Áö¼Ó°¡´É¼º¿¡ ´ëÇÑ ³ë·Â°ú ÀÏÄ¡Çϸç, IoT ±â´ÉÀ» ÅëÇÕÇÑ ½º¸¶Æ® Æ÷Àå ±â¼úÀº º¸°ü ¹× ¿î¼Û Áß »óÅ ¸ð´ÏÅ͸µÀÌ °¡´ÉÇÏ¿© Á¦Ç° ¾ÈÀü°ú ȯÀÚ ÄÄÇöóÀ̾𽺸¦ °ÈÇÒ ¼ö ÀÖ½À´Ï´Ù. ½À±â, ºû, ¿Âµµ º¯È¿¡ ´ëÇÑ À庮 Ư¼ºÀ» °³¼±ÇÑ Ã·´Ü ¼ÒÀç´Â Á¦Ç°ÀÇ À¯Åë±âÇÑÀ» ¿¬ÀåÇϰí È¿´ÉÀ» À¯ÁöÇÕ´Ï´Ù. ¶ÇÇÑ Åõ¿©¸¦ ¿ëÀÌÇÏ°Ô ÇÏ´Â ¼ÒÀç´Â ȯÀÚÀÇ »ç¿ë°¨À» Çâ»ó½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº º¸´Ù È¿À²ÀûÀÎ Á¦Á¶ °øÁ¤°ú Àç·á Æó±â¹°ÀÇ °¨¼Ò¸¦ ÅëÇØ ºñ¿ë Àý°¨À» °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù.
Á¦ÇÑµÈ Àνİú ¼ö¿ë
Ä¡·áÀû ÀÌÁ¡¿¡µµ ºÒ±¸ÇÏ°í ¹®ÈÀû ±Ý±â¿Í Á÷Àå ¹× Áú³» Åõ¿©¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ºÒÆíÇÔÀÌ ¸¹Àº Áö¿ª¿¡¼ äÅÿ¡ ´ëÇÑ ÀúÇ×À» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õµéµµ ȯÀÚ°¡ ½È¾îÇÑ´Ù´Â ÀÎ½Ä ¶§¹®¿¡ Á¾à ó¹æÀ» ÁÖÀúÇÏ´Â °æ¿ì°¡ ÀÖÀ¸¸ç, ½ÃÀå ħÅõ¸¦ Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °æ±¸¿ë ÀǾàǰ°ú ºñ±³ÇßÀ» ¶§ Á¾àÀÇ ÀûÀýÇÑ Åõ¿© ±â¼ú°ú ÀÌÁ¡¿¡ ´ëÇÑ ±³À°ÀÌ ºÎÁ·ÇÏ´Ù´Â Á¡µµ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦´Â ´ëü Åõ¿© ¹æ¹ýÀ» ¼±È£ÇÏ´Â º¸¼öÀûÀÎ »çȸ¿Í ½ÅÈï ½ÃÀå¿¡¼ ƯÈ÷ µÎµå·¯Áý´Ï´Ù.
COVID-19 ÆÒµ¥¹ÍÀº Ãʱ⿡´Â °ø±Þ¸Á ¹®Á¦¿Í Á¦Á¶ Á¦ÇÑÀ» ÅëÇØ ÁÂ¾à Æ÷Àå ½ÃÀåÀ» È¥¶õ¿¡ ºü¶ß·È½À´Ï´Ù. ±×·¯³ª ÀÌ À§±â´Â ÀÌÈÄ ÀǾàǰ Æ÷ÀåÀÇ ¹«°á¼º°ú ¹«±Õ¼º¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â µî ƯÁ¤ ½ÃÀå µ¿ÇâÀ» °¡¼ÓÈÇß½À´Ï´Ù. ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ÀǾàǰÀÇ ¾ÈÀü°ú ¾ÈÁ¤¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ °íǰÁú Æ÷Àå ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ÇコÄÉ¾î »ê¾÷ÀÇ »õ·Î¿î °úÁ¦¿¡ ´ëÇÑ ºü¸¥ ÀûÀÀÀº º¸È£ ±â´ÉÀÌ °ÈµÈ ÁÂ¾à Æ÷Àå µðÀÚÀÎ, °¡Á¤¿¡¼ ¾ÈÀüÇÏ°Ô »ç¿ëÇÒ ¼ö ÀÖ´Â °£ÆíÇÑ Åõ¾à ¹æ¹ý µî ÀǾàǰ Æ÷ÀåÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇß½À´Ï´Ù.
¿¹Ãø ±â°£ Áß ¾Ë·ç¹Ì´½/PE(Alu/PE) ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Ë·ç¹Ì´½/PE(Alu/PE) ºÎ¹®Àº ¿ì¼öÇÑ À庮 Ư¼º°ú ±â´É¼ºÀÇ Á¶ÇÕÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Æ÷ÀåÀç´Â ½À±â, ºû, »ê¼Ò, ¿À¿° ¹°Áú·ÎºÎÅÍ ¿ì¼öÇÑ º¸È£ ±â´ÉÀ» Á¦°øÇÏ¿© Á¾à Á¦Á¦ÀÇ ¾ÈÁ¤¼º°ú À¯È¿¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ÀÌ ¼ÒÀçÀÇ ÈÇÐÀû ºÒȰ¼º Ư¼ºÀº ¹ÐºÀµÈ ¾à¹°°úÀÇ »óÈ£ ÀÛ¿ëÀ» ¹æÁöÇϰí, ¹°¸®Àû ³»±¸¼ºÀº Ãë±Þ ¹× ¿î¼Û Áß¿¡ ¼¶¼¼ÇÑ Á¾àÀ» º¸È£ÇϹǷΠÀü ¼¼°è Á¦¾àȸ»çµéÀÌ ¼±È£Çϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß ¿äµµ ¿µ¿ªÀÌ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¹Ãø ±â°£ Áß ºñ´¢±â°ú ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Ç¥Àû ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ¿äµµ ºÎ¹®ÀÌ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿äµµ Á¾àÀº ±¹¼Ò Ä¡·á°¡ ÇÊ¿äÇÑ Áúȯ¿¡ Á÷Á¢ÀûÀ̰í È¿À²ÀûÀÎ ¾à¹° Åõ¿©¸¦ Á¦°øÇϸç, °æ±¸¿ë ¾à¹°¿¡ ºñÇØ Àü½Å ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¾à¹°Àü´Þ ±â¼úÀÇ ¹ß´Þ·Î ¿äµµ Á¾àÀÇ È¿´É°ú ÆíÀǼºÀÌ °³¼±µÇ¸é¼ ÀÇ·áÁø »çÀÌ¿¡¼ ¿äµµ Á¾àÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ´¢±â Áúȯ¿¡ ´ëÇÑ À¯º´·üÀÌ ³ôÀº °í·ÉÈ Àα¸ Áõ°¡´Â ÀÌ·¯ÇÑ Æ¯¼öÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß À¯·´ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ±âŸ Áö¿ª¿¡ ºñÇØ Á¦¾à »ê¾÷ÀÌ Àß ¹ß´ÞµÇ¾î ÀÖ°í, ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, Á¾àÀ̶ó´Â Á¦Çü¿¡ ´ëÇÑ ¹®ÈÀû ¼ö¿ëµµ°¡ ³ô±â ¶§¹®ÀÔ´Ï´Ù. À¯·´ ±¹°¡µéÀº 󹿾à°ú ÀϹÝÀǾàǰ ¸ðµÎ Á¾àÀ» »ç¿ëÇÏ´Â ¿À·£ ÀüÅëÀ» °¡Áö°í ÀÖÀ¸¸ç, °íǰÁú Æ÷Àå ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¾ÈÁ¤ÀûÀÎ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÀǾàǰ Æ÷Àå¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁصµ Á¦Ç°ÀÇ ¾ÈÁ¤¼º°ú ¾ÈÀü¼ºÀ» º¸ÀåÇÏ´Â °í±Þ Æ÷ÀåÀçÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯·´ÀÇ °í·ÉÈ¿Í ÀÇ·áºñ ÁöÃâ Áõ°¡´Â À¯·´ ÁÂ¾à Æ÷Àå ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÇコÄɾî ÀÎÇÁ¶óÀÇ È®Àå, ÀǾàǰ Á¦Á¶ Ȱµ¿ Áõ°¡, Àεµ ¹× Áß±¹°ú °°Àº ±¹°¡ÀÇ ÇコÄɾî ÁöÃâ Áõ°¡·Î ÀÎÇØ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ Àα¸ Áõ°¡¿Í ÀÇ·á ¼ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀ¸·Î ÀÎÇØ Å« ½ÃÀå ±âȸ°¡ âÃâµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ã·´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÇ·á ÇöÀå¿¡¼ Á¾à ÇüÅÂÀÇ Á¾àÀÌ Á¡ÁøÀûÀ¸·Î ¼ö¿ëµÇ¸é¼ ÀÌ Áö¿ª Àüü ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
According to Stratistics MRC, the Global Suppository Packaging Market is accounted for $423.04 million in 2024 and is expected to reach $660.20 million by 2030 growing at a CAGR of 7.7% during the forecast period. Specialized packaging options made to safeguard, store, and administer suppository drugs are referred to as suppository packaging. These packaging's guard against contamination while guaranteeing product integrity, hygienic practices, and convenience of administration. To preserve product efficacy, suppository packaging needs to offer barrier protection against moisture, light, and temperature changes. It is extensively utilized for vaginal and rectal suppositories in the pharmaceutical and medical sectors.
Rising healthcare expenditure
The increasing healthcare expenditure globally is a significant driver for the suppository packaging market. As governments and individuals allocate more resources to healthcare, there is greater investment in pharmaceutical products, including suppositories. This financial commitment enables the development and adoption of advanced drug delivery systems, creating demand for high-quality packaging solutions. The aging population, particularly in developed regions, further accelerates this trend as older demographics require more medications.
Stringent regulatory approvals
Regulatory bodies like the FDA impose rigorous standards for pharmaceutical packaging to ensure product safety, stability, and efficacy. These regulations necessitate extensive testing, documentation, and compliance procedures, which extend product development timelines and increase costs for manufacturers. Additionally, regulations vary across regions, requiring companies to adapt their packaging solutions to meet different standards in various markets. These challenges particularly affect smaller manufacturers who may struggle with the financial and technical resources needed to navigate complex regulatory landscapes.
Innovations in packaging materials
The development of biodegradable and eco-friendly materials addresses growing environmental concerns and aligns with sustainability initiatives in the pharmaceutical industry. Smart packaging technologies incorporating IoT features enable condition monitoring during storage and transit, enhancing product safety and patient compliance. Advanced materials with improved barrier properties against moisture, light, and temperature fluctuations extend product shelf life and maintain efficacy. Additionally, materials that facilitate administration improve patient experience. These innovations potentially reduce costs through more efficient manufacturing processes and reduced material waste.
Limited awareness and acceptance
Despite their therapeutic advantages, cultural taboos and patient discomfort regarding rectal or vaginal administration methods create resistance to adoption in many regions. Healthcare providers may also hesitate to prescribe suppositories due to perceived patient reluctance, limiting market penetration. Additionally, the lack of education about proper administration techniques and benefits of suppositories compared to oral medications further constrains market growth. This challenge is particularly pronounced in conservative societies and emerging markets where alternative delivery methods are preferred.
The COVID-19 pandemic initially disrupted the suppository packaging market through supply chain challenges and manufacturing restrictions. However, the crisis subsequently accelerated certain market trends, including increased focus on pharmaceutical packaging integrity and sterility. The pandemic heightened awareness about medication safety and stability, driving demand for high-quality packaging solutions. Additionally, the healthcare industry's rapid adaptation to new challenges during the pandemic fostered innovation in pharmaceutical packaging, including suppository packaging designs with enhanced protective features and user-friendly administration methods that could be used safely at home.
The aluminum/PE (Alu/PE) segment is expected to be the largest during the forecast period
The aluminum/PE (Alu/PE) segment is expected to account for the largest market share during the forecast period due to its superior combination of barrier properties and functionality. This packaging material provides excellent protection against moisture, light, oxygen, and contaminants, ensuring the stability and efficacy of suppository formulations until use. The material's chemical inertness prevents interaction with the enclosed medication, while its physical durability protects delicate suppositories during handling and transportation, making it the preferred choice for pharmaceutical manufacturers worldwide.
The urethral segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the urethral segment is predicted to witness the highest growth rate due to the increasing prevalence of urological conditions and advancements in targeted drug delivery systems. Urethral suppositories provide direct and efficient medication administration for conditions requiring localized treatment, reducing systemic side effects compared to oral medications. Developments in drug delivery technologies have improved the efficacy and comfort of urethral suppositories, driving their adoption among healthcare professionals. Additionally, the growing aging population, who experience higher rates of urological issues, further fuels demand for these specialized treatment options.
During the forecast period, the Europe region is expected to hold the largest market share owing to a well-established pharmaceutical industry, advanced healthcare infrastructure, and greater cultural acceptance of suppository dosage forms compared to other regions. European countries have long-standing traditions of suppository use in both prescription and over-the-counter medications, creating a stable demand for high-quality packaging solutions. The region's stringent regulatory standards for pharmaceutical packaging also drive the adoption of premium packaging materials that ensure product stability and safety. Additionally, Europe's aging population and increasing healthcare expenditure further contribute to the sustained growth of the suppository packaging market across the continent.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by expanding healthcare infrastructure, increasing pharmaceutical manufacturing activities, and rising healthcare expenditure across countries like India and China. The region's large and growing population, coupled with improving access to healthcare services, creates substantial market opportunities. Additionally, increasing awareness about advanced drug delivery systems and the gradual acceptance of suppository dosage forms in medical practice are further accelerating market growth throughout the region.
Key players in the market
Some of the key players in Suppository Packaging Market include NextPharma Technologies, CordenPharma, Recipharm AB, Valmatic S.R.L., Sarong S.p.A., Key International, HySum Europe GmbH, FAMAR Health Care Services, Hudi Pharma HQ, Adragos Pharma, LGM Pharma, Aluberg s.p.a., Delpharm, Unither, Trefoil Packaging Pvt Ltd and Gerresheimer AG.
In October 2022, CordenPharma Launches Oral Solid Dose GMP Manufacturing for Clinical Trial Development. Because Oral Solid Dose (OSD) capabilities are in high demand, CordenPharma made the strategic decision to enhance our offering with an investment of €10 million into the design and installation of a new GMP Clinical Trial Development (CTD) facility located in CordenPharma Plankstadt (DE). The installment of the new CTD facility is a response to our customers' demands and the recognition of gaps in scale and technologies.
In October 2022, Swedish multinational CDMO Recipharm has bolstered its sterile filling capabilities at its facility in Kaysersberg, France, by installing Lab+ continuous automated technology. The low-volume blow-fill-seal (BFS) process has a throughput speed of 2,000 doses per hour and can be easily adapted for a range of different product types and dosage designs, Recipharm said.